Browsing Tag
Cancerguard
2 posts
What does Abbott’s Cancerguard AACR data mean for multi-cancer early detection and the $21bn Exact Sciences acquisition?
Abbott presents Cancerguard dual-biomarker MCED data at AACR 2026. What the DETECT-A survival findings mean for ABT, GRAIL, and cancer screening. Read more.
Abbott (ABT) closes $21bn Exact Sciences deal, making it the leader in U.S. cancer screening diagnostics
Abbott (ABT) closes its $21bn Exact Sciences acquisition, creating a $12bn+ diagnostics leader in cancer screening and precision oncology. Read the full analysis.